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Abstract
Irritable bowel syndrome (IBS) is a gut-brain disorder in which symptoms are shaped
by serotonin acting centrally and peripherally. The serotonin transporter gene SLC6A4
has been implicated in IBS pathophysiology, but the underlying genetic mechanisms
remain unclear. We sequenced the alternative P2 promoter driving intestinal SLC6A4
expression and identified single nucleotide polymorphisms (SNPs) that were associated with IBS in a discovery sample. Identified SNPs built different haplotypes, and
the tagging SNP rs2020938 seems to associate with constipation-predominant IBS
(IBS-C) in females. rs2020938 validation was performed in 1978 additional IBS patients and 6,038 controls from eight countries. Meta-analysis on data from 2,175 IBS
patients and 6,128 controls confirmed the association with female IBS-C . Expression
analyses revealed that the P2 promoter drives SLC6A4 expression primarily in the
small intestine. Gene reporter assays showed a functional impact of SNPs in the P2
region. In silico analysis of the polymorphic promoter indicated differential expression regulation. Further follow-up revealed that the major allele of the tagging SNP
rs2020938 correlates with differential SLC6A4 expression in the jejunum and with
stool consistency, indicating functional relevance. Our data consolidate rs2020938 as
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a functional SNP associated with IBS-C risk in females, underlining the relevance
of SLC6A4 in IBS pathogenesis.
KEYWORDS

5-HT, IBS, IBS-C , serotonin transporter

1 | I NTRO D U C TI O N

A 44-bp insertion/deletion polymorphism, 5-HTTLPR (short,
long: s/l), in the P1 promoter of SLC6A4 had been associated with

Accumulating evidence has shown that irritable bowel syndrome

IBS, although some studies have failed to confirm this association (for

(IBS) is not just a functional gastrointestinal (GI) disorder, but rather

a summary, see11 ). The s allele of promoter P1 is a less potent driver

1,2

represents a prototypical gut-brain disorder.

IBS patients pres-

of mRNA expression, so may diminish serotonin re-uptake, leading to

ent with abdominal pain and variable alterations in bowel habits,

higher 5-HT levels and increased bioavailability in the gut.12,15 5-HT

which define the subtype of IBS. These subtypes are diarrhoea-

levels were higher in rectal biopsies of IBS-D patients compared with

predominant IBS (IBS-D), constipation-predominant IBS (IBS-C),

biopsies from healthy individuals or individuals with IBS-A or IBS-

IBS is one of the

C.16 These 5-HT levels were significantly higher in carriers of the s/s

common GI disorders, and depending on the applied diagnostic

genotype than in carriers of the s/l or l/l genotype.16 Increased 5-HT

Rome criteria, it has a prevalence of 10.1% (Rome III) and 4.1% (Rome

levels and the s/s genotype correlated significantly with IBS-D and

IV) worldwide,4 and 70%-75% of affected individuals are female. 2,5

abdominal pain,16 whereas the l/l genotype was associated with IBS-

mixed IBS (IBS-M) or unspecified IBS (IBS-U).

2,3

Bidirectional communication between the gut and the brain via
the gut-brain axis is influenced by the immune system, hormones
and neurotransmitters.

2,3

C. The s/l genotype correlated with SERT protein expression (SERT
expression was lower in colon biopsies of s allele carriers).15,16

Serotonin, or 5-hydroxytryptamine (5-

The P1 s/l polymorphism is also associated with behavioural traits

HT), acts as a neurotransmitter, paracrine factor, endocrine hor-

and psychiatric conditions like anxiety and depression that are often

mone and growth factor to connect the gut and the brain.6 Enteric

comorbid with IBS, supporting the biopsychosocial model of IBS.13,17,18

5-HT regulates a range of gut functions, including GI motility, se-

Furthermore, stress is involved in shaping the phenotype.19,20 These

6

cretion and visceral sensation. Of note, alterations in both central

findings suggest that the P1 s/l polymorphism might alter central neu-

and peripheral 5-HT contribute to visceral hypersensitivity in IBS.7

robiological functions in the brain to induce behavioural phenotypes.

Furthermore, 5-HT influences behaviour and modulates the immune

Disturbed GI function is well documented in IBS, but the underly-

and nervous systems. It affects the vagus nerve and is involved in

ing neuromolecular mechanisms are not well understood. Serotonin

the GI symptoms and comorbid disorders associated with IBS.6,8,9 In

metabolism is altered in IBS, and normalizing serotonin levels can

line with its important gut-related functions, serotonin is predom-

ameliorate IBS symptoms. 2,21 Studies have revealed variable results

10

inantly produced in the gut and is influenced by gut microbiota.

regarding levels of 5-HT and its metabolites in IBS,15,22-25 but SERT

IBS is caused by extrinsic factors such as stress, infection and diet,

expression was consistently found reduced in GI tissues of IBS pa-

as well as intrinsic factors including the individual genetic background

tients, which supports findings of increased 5-HT in the tissue or

and microbiota.7,11 One of the most extensively analysed genes in

blood. 22,23 How genetic factors affect 5-HT in IBS is still poorly

IBS is SLC6A4 (NM_001045), which encodes the serotonin re-uptake

understood. Unravelling these genetic mechanisms may help to de-

transporter (SERT).11 This transporter is responsible for the re-uptake

velop effective, individualized treatment strategies for IBS.

of serotonin from the synaptic cleft into the presynaptic neuron and
from the interstitial space into the gut epithelium and enterocytes.
The expression of different 5’ SLC6A4 isoforms is driven by two
distinct promoters—P1 and P2

12-14

In this study, we aimed to elucidate the impact of the alternative
P2 promoter of SLC6A4 in IBS pathogenesis. We sequenced the P2
region of SLC6A4 in a discovery sample from the United Kingdom

(Figure 1). P1 controls the ex-

and identified SNPs that were associated with IBS-C in females. To

pression of isoforms 1a and 1b, which have non-coding exons repre-

validate the initial association of the SNPs with IBS-C , we genotyped

senting alternatively used 5’ untranslated regions (5’UTRs) upstream

a tagging SNP in eleven cohorts from eight additional countries.

of exon 2. A novel SLC6A4 isoform is generated when exon 1c and

Meta-analysis confirmed the initial finding. Follow-up analyses of

1b are spliced to exon 2, and expression of this isoform is driven by

associated variants were performed by luciferase reporter assays

the P2 promoter downstream of P1 (Figure 1). This novel isoform is

to assess their functional impact. Expression analysis in different GI

predominantly expressed in the GI tract.14

regions uncovered the relevance of the P1- and P2-driven isoforms
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in the gut. We also analysed the functional impact on promoter reg-

research protection programme (IRB#12-0 01802-CR-0 0004).

ulation in silico. The genotype-phenotype correlations revealed the

Furthermore, a cohort of IBS patients and controls from the

functional consequences of the identified SNPs.

United Kingdom, United States and Canada were included in
this study; these were kindly provided by Glaxo Smith Kline (UK,
GenIBS/2005/0000/01).

2 | M ATE R I A L A N D M E TH O DS
The experimental design is summarized in Figure S1. Variants

2.2 | Preparation of genomic DNA

were detected using biospecimens from human subjects, and in
vitro and in silico analyses determined the functional relevance of

Genomic DNA was prepared from blood or saliva samples taken

these detected variants. Additional information can be found in the

from patients and healthy controls as described previously. 27,28

Supplementary Data.

2.3 | Genotyping of the tag SNP rs2020938

2.1 | IBS patients and controls

Unless otherwise stated in the Supplementary Methods section,
SNP analysis was carried out on IBS patient and control DNA from

SNP genotyping of the tagSNP rs2020938 in patients and controls

IBS expert centres, comprising twelve cohorts from eight coun-

from the IBS expert centres was carried out using the KASPar®

tries including Chile, Germany, Greece, Ireland, Spain, Sweden, the

assay (KBiosciences, Ltd., Hoddesdon, United Kingdom) according

United Kingdom and the United States (Table S1). Comparative

to the manufacturer's instructions (for primer sequences, Table S4).

SLC6A4 expression analyses were performed on small and

Thermal cycling was performed in a Mastercycler vapo.protect ther-

large intestine biopsies from three case-control cohorts from

mal cycler (Eppendorf). An initial 15 minutes incubation at 95℃ was

Spain (Barcelona) and Germany (Berlin and Erlangen-Nürnberg)

followed by 20 cycles consisting of 10 seconds at 94℃, 5 seconds

(Table S2).

at 57℃, and 10 seconds at 72℃, followed by 23 cycles consisting

All participants were Caucasian. Written informed consent was

of 10 s at 94℃, 5 seconds at 57℃, and 10 seconds at 72℃. After

obtained from all subjects, and experiments were performed in ac-

thermal cycling, results were analysed using the fluorescence plate

cordance with the principles of the WMA Declaration of Helsinki

reader of the 7500 Fast Real-Time PCR System (Applied Biosystems).

and the Department of Health and Human Services Belmont

Genotyping was repeated in 10% of the samples as a quality control

Report. All studies were approved by the following local ethics

measure, and the same results were obtained.

committees: Germany, Heidelberg: Ethical Committee, Medical
Faculty of the Heidelberg University Hospital (S067/2010);
Germany, Berlin: Ethical Committee Charité Berlin Campus Mitte

2.4 | Statistical analysis

(No Si 285); Germany, Erlangen, Ethical Committee, Medical
Faculty of the University of Erlangen-Nürnberg (Ethik No. 4581);

2.4.1 | Statistical analysis of the genotyping data

Chile, Santiago: Ethical Committee Hospital Clínico Universidad
de Chile (Acta-No 25/2015, No 27/2019); Greece, Athens: Ethical

Genotype frequencies, association analyses and tests for deviation

committee of the Aretaieio University Hospital, Medical School,

from the Hardy-Weinberg Equilibrium (HWE) were compared as

National and Kapodistrian University of Athens (008/21-11-2017);

described previously. 27 Genotype relative risks of IBS and IBS sub-

Ireland, Cork: Clinical Research Ethics Committee (APC024);

types were quantified by odds ratios (ORs) with the corresponding

Spain, Barcelona: Ethics Committee of Hospital Universitari

95% confidence intervals (CIs) based on a logistic regression model

Vall d´Hebron (PR(AG)159/2011) and Ethics Committee of Par

under a dominant inheritance model (TT compared with TC and CC

de Salut Mar (2005/2106/I); Sweden, Stockholm: Karolinska

genotypes). 29

Institutet's Ethics Review Board (dnr 2009/1059-31/3); Sweden,
Gothenburg: Regional Ethical Review Board in Gothenburg (S489-
02 and 731-0 9); United Kingdom, Manchester: NHS National
Research Ethics Service, South Manchester Research Ethics

2.4.2 | Statistical analysis for genotype-phenotype
associations in German IBS-Net samples

Committee, Genetics of Functional GI Disorders (09/H1003/1);
United Kingdom, Nottingham: clinical trial clinicaltrials.gov (iden-

Groups were compared (genotype status of SLC6A4 SNPs) according

tifier NCT00745004), approved by Nottingham Research Ethics

to the following clinical phenotype features: IBS subtype (using the

26

Committee 2 (REC reference number 08/H0408/134) ; USA, St.

ROME III criteria); stool consistency (using the Bristol stool scale [BSS])

Louis, WA: Washington University in St. Louis, Human Research

and stool frequency and IBS symptom severity (using the IBS symptom

Protection Office (IRB ID #: 201 103 220); USA, Los Angeles, CA:

severity scale) in 134 female IBS patients from German IBS-Net sam-

University of California Los Angeles, HORPP Office of the human

ples. Chi-square tests were used to analyse differences in frequencies

|
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F I G U R E 1 Schematic showing the upstream region of SLC6A4 including the promoter regions P1 and P2. Oval shapes represent exons,
and connecting lines indicate introns. Upstream regions of the start ATG (5’untranslated region [5’UTR]) are indicated by a light yellow line.
Alternative upstream non-coding exons are indicated in light blue/green and downstream coding exons are labelled in dark green. Exons 1a,
1b, 1c and 2, promoter 1 (P1) and the alternative promoter 2 (P2) are indicated (adapted from14). Not drawn to scale

of IBS subtype (IBS-C, IBS-D, IBS-M and IBS-U) and stool consistency

5'UTR including exons 1c and 1b were screened for genetic variants

(hard, soft, normal). Additionally, non-parametric Kruskal-Wallis tests

(Figure 1).

were conducted to analyse potential differences in stool frequency

Sequence data were compared with the SLC6A4 reference

and IBS symptom severity. P-values <.05 were considered statistically

sequence

significant; a P-value <.10 was considered a trend. Analyses were car-

re/224589808) to assess genetic variability in the P2 promoter.

NC_000017

(http://www.ncbi.nlm.nih.gov/nucco

ried out using IBM SPSS Statistics for Windows, version 25.

Twelve sequence variants were identified, seven of which were
common SNPs with a minor allele frequency (MAF) above 0.05

2.5 | Meta-analysis
Results from single studies were combined using fixed and random effects meta-analyses. Results were represented by Forest plots as fol-

(Table S8).

3.2 | Identified variants are associated with IBS-C
in the discovery cohort of female patients

lows: CIs on the OR for each study were indicated by horizontal lines,
study-specific ORs by squares proportional to the study size and com-

Association analysis, assuming a dominant model, revealed IBS-C to

bined summary estimates by a diamond with horizontal limits indicat-

be nominally associated with five of the seven common SNPs tested

ing the confidence limits. Data were analysed using the rmeta package

(Table 1).

from the free Software Environment for Statistical Computing R.

Further analysis applying the dominant model revealed a nominal
association between IBS-C and the five associated SNPs in female

3 | R E S U LT S
3.1 | Seven common variants identified in the
SLC6A4 P2 promoter in a discovery cohort from the
United Kingdom
The alternative promoter P2 of SLC6A4 primarily drives expression

patients. However, due to the small sample size for males an association cannot be excluded (Table 2).
No deviation from HWE was detected in any groups other than
IBS-C and female IBS-C (Table S9).

3.3 | Haplotype block analysis identified a tag SNP
for follow-up analyses in female IBS-C patients

of the serotonin transporter in the GI tract.14 To see whether genetic variants within this alternative promoter might regulate ex-

Haplotype analysis of the seven common SNPs in female IBS-C

pression and thus contribute to or protect from IBS, we performed

patients and female controls was performed using Haploview v4.2

Sanger sequencing of this genomic region in a discovery cohort from

(https://www.broadinstitute.org/haploview/haploview). All SNPs

the United Kingdom consisting of 197 IBS patients (98 IBS-D, 99

displayed a high linkage disequilibrium (LD), defining one haplo-

IBS-C) and 90 healthy control individuals. In this initial analysis, a

type block with three common haplotypes (Figure 2A). The SNP

1,319-bp spanning region of the P2 promoter and the downstream

rs2020938 was selected as a representative tag SNP for subsequent

8052
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TA B L E 1 SNP association data of IBS-C patients from the
discovery cohort compared with healthy volunteers, both from the
United Kingdom

3.4 | Functional readout of SNPs in luciferase
reporter assays

P
(dominant
model)

To investigate the functional relevance of the SNPs arranged in the

SNP

OR

CI [lower;
upper]

rs12150214

0.41

0.21;0.8

.008

luciferase reporter cassette and sequence verified (Figure 2B). The

rs2020936

0.39

0.2;0.77

.006

major and minor haplotype reporter constructs were analysed in

rs2020937

0.91

0.47;1.76

.788

four human cell lines: HEK293T embryonic kidney cells, SH-SY5Y

two haplotype blocks, representative genomic regions were amplified from the genome of respective carriers, cloned upstream of a

rs2029038

0.44

0.23;0.85

.014

neuroblastoma cells, as well as Caco 2 and Colo 320, both colon car-

rs2020939

1.34

0.7;2.54

.373

cinoma cells (Figure 2C). All cell lines endogenously express SLC6A4

rs25528

0.44

0.23;0.87

.017

as shown by RT-PCR (see Figure S2). Luciferase reporter assays re-

rs6354

0.46

0.24;0.9

.023

Note: P-values for the dominant model (TT compared with TC and CC
genotypes). P-values <.001 were rated significant after Bonferroni
correction. P-values smaller than 0.05 were considered ‘nominal
associations’ a priori. OR, odds ratio; CI, confidence interval.

TA B L E 2 SNP association data of common SNPs (MAF > 0.05)
separated by sex in IBS-C patients from the discovery cohort
compared with female/male healthy volunteers, both from the
United Kingdom

vealed that the minor haplotype in the P2 promoter region carrying
the rs2020938 variant drives less gene expression than the major
haplotype does in all four cell lines (Figure 2C).

3.5 | Replication analysis of rs2020938 in twelve
additional cohorts from eight countries confirmed the
association with IBS-C in female patients
To validate the association between rs2020938 and IBS-C in female
patients from the UK discovery sample, we genotyped rs2020938

OR

CI [lower;
upper]

P
(dominant
model)

rs12150214

0.41

0.20;0.83

.012

rs2020936

0.39

0.19;0.78

.008

rs2020937

1.14

0.57;2.27

.715

rs2029038

0.39

0.20;0.78

.007

Meta-analysis of genotype data from 2,175 IBS patients and

rs2020939

1.14

0.58;2.24

.705

6,128 controls confirmed the association between rs2020938 and

rs25528

0.44

0.22;0.89

.021

IBS-C in female patients (OR = 0.75 and 0.78, P = .0458 and .05

rs6354

0.47

0.23;0.95

.036

using a fixed and random effects model) (Figure 3A). Analyses in-

SNP
Females

in 1978 additional IBS patients and 6,038 controls from twelve cohorts in eight countries: two from the United Kingdom, two from
Germany, three from the United States and one each from Ireland,
Sweden, Spain, Greece and Chile (Table S3). Cohorts with 30 or
fewer individuals in subgroup analyses were not included in the
meta-analysis. The average number of IBS patients per study was
167 (range, 34-455).

volving male patients or non-IBS-C subtypes did not show a statisti-

Males
rs12150214

0.42

0.04;4.18

.428

rs2020936

0.42

0.04;4.18

.428

rs2020937

0.15

0.01;1.50

.071

rs2029038

1.27

0.18;8.79

.808

rs2020939

NA

0.00;NA

.1528

rs25528

0.48

0.05;4.81

.508

rs6354

0.37

0.04;3.65

.357

Note: P-values of the dominant model. P < .001 was rated significant
after Bonferroni correction. P < .05 was rated nominally a priori. OR,
odds ratio; CI, confidence interval.

cally significant association (data not shown).
In all control individuals and most IBS patients, no deviations
from HWE expectations were detected except for IBS-C and female
IBS-C patients from the United Kingdom (P = .027-0.041) and IBS

overall, IBS-C and female IBS-C patients from Greece (P = 1.65 × 10 -

12

-1.68 × 10 -12) (Table S9).

3.6 | Comparative expression analysis of SLC6A4 in
different GI regions
Analysis of expression driven by the P1 and P2 promoter in different

analyses because it showed the strongest association with IBS-C in

intestinal regions confirmed that the P2 promoter primarily drives

female patients (P = .007; OR, 0.39; CI, 0.2-0.78). To determine the

SLC6A4 expression within the small intestine. In particular, robust

functional relevance of these SNPs, we further analysed the two

expression was detected in the jejunum (Ct: 27-31) and even more

most contrary blocks, AATTTC and CCCCTCG, hereafter termed

pronounced in the ileum (Ct: 22-27). In contrast, within the large in-

major and minor, respectively.

testine Ct values were much higher, within colon (Ct: 30-37) and the

|
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F I G U R E 2 A, Genomic structure and linkage disequilibrium (LD) of the SNP markers in the SLC6A4 P2 promoter region in female patients
with IBS-C . Strong LD is indicated by bright red (LOD ≥2, D' = 1), and no LD is indicated by white (LOD < 2, D' < 1). Pink (LOD = 2, D' < 1)
and blue (LOD < 2, D' = 1) indicate intermediate LD. Association analyses of block 1 for IBS patients versus controls revealed five significant
P-values. All SNPs with a MAF > 5% were included. The analysed genomic region is shown as a white bar above. The relative positions of
SNPs within this region are represented by vertical lines. The graphics underneath show the degree of LD among the SNPs. Red boxes
without numbering represent a LD value of 100 (source: Haploview; Copyright (c) 2003-2006 Broad Institute of MIT and Harvard). The
tag SNP rs2020938 was selected for subsequent replication analysis. B, Schematic of the cloned upstream region of SLC6A4 including the
promoter regions P1 and P2, which harbour the major and minor haplotypes. The scheme is not drawn to scale. Boxes indicate exons, and
lines indicate introns. ATG indicates the start codon. The upstream region of the ATG is indicated in light green, the downstream region
in grey. Exons 1a, 1c, 1b, and 2 and the P1 and P2 promoters are illustrated. C, Data of the gene reporter luciferase assay. The promoter
activities of the alternative SLC6A4 promoter P2, composed of the major or the minor haplotype and harbouring the tag SNP rs2020938,
were analysed in HEK293T, Colo 320, Caco 2 and SH-SY5Y cells. Relative luciferase activities are indicated (mean ± SE). Firefly luciferase
values were normalized relative to renilla luciferase values; the number of performed experiments (n = 9-15; * P < .05, ** P < .01, ***
P < .001, **** P < .0001) was corrected for multiple testing using the Benjamini, Krieger and Yekutieli procedure

sigma (Ct 31-37) and thus, the P2-driven isoform not found to be

carriers from the Spanish centre. This revealed a significant correla-

consistently expressed. Of note, the P1 promoter-driven transcript

tion between SLC6A4 expression and stool consistency (assessed by

was neither detectable at a robust level in the small nor in the large

the BSS) in TC cases only (r = .75; P = .02) (Figure 3D). Hence, lower

intestine (Table S10). This is in line with expression data of different

SLC6A4 expression in TC carriers is associated with softer stools.

tissues from the GTEx portal (Release v08, https://gtexportal.org/

These findings were corroborated by genotype-phenotype as-

home/), which shows highest expression in the lung, followed by the

sociation data (IBS subtype, stool consistency, stool frequency and

small intestine (terminal ileum, data from n = 187 donors, median

IBS symptom severity) of 134 female IBS patients from the IBS-

TPM (transcripts per million) = 4.219). Expression in other tissues was

Net in Germany. No associations were found for IBS subtype, stool

much lower (eg oesophagus, n = 555 donors, median TPM = 1.645,

frequency or symptom severity. However, SLC6A4 TC/CC carriers

all others: median TPM below 0.2). In addition, isoform-specific ex-

showed a trend for softer stools (according to the BSS) compared

pression analysis confirmed that the P2-driven isoform is the most

with TT carriers (P = .053).

abundantly expressed isoform in the small intestine (Figure 4).
Further follow-up studies in tissue samples of IBS patients and
controls revealed that the homozygous genotype TT of the major
allele of rs2020938 correlated with significantly altered expression

3.8 | Impact of DNA variants on transcription factor
binding capacity

in the jejunum (P = .0398), corroborating a functional impact of the
SNP on SERT expression (Figure 3B). In contrast, overall expres-

We performed comparative transcription factor binding site analysis

sion was not different between IBS patients and control individuals

in the major and the minor (protective) haplotype genomic regions

(Figure 3C). Moreover, ileum samples from a German centre showed

where the tag SNP rs2020938 resides. We used the ePOSSUM2

no correlation with the rs2020938 genotype, potentially because of

online tool (https://www.mutationdistiller.org/ePOSSUM2/) to

the small number of variant carriers (data not shown).

predict the impact of DNA variants on transcription factor binding. This revealed 52 novel binding sites in the variant sequence,

3.7 | Genotype-phenotype correlation

32 of which were predicted by more than three models (Table S11).
Ingenuity pathway analysis assembled these genes into three major
networks according to the top diseases and functions as follows: 1.

Correlation analysis of nCounter expression data of jejunum sam-

gene expression, cell cycle and cellular development; 2. gene ex-

ples was performed separately in IBS patients of TT or TC genotype

pression, cell morphology and humoral immune response; and 3.
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F I G U R E 3 A, Forest plots illustrating genotype risks of rs2020938 of IBS-C in females. Genotype risk is shown as odds ratios (OR)
with corresponding 95% confidence intervals (CIs) and is based on a logistic regression model under dominant genetic penetrance. CIs for
each study are indicated by horizontal lines, ORs by squares that reflect study sizes, and summary estimates by diamonds with horizontal
limits at confidence limits and with a width inversely proportional to the standard error. Only data sets with more than 30 individuals per
genotype group were included. The I2 of 24% and τ2 of 0.03 suggest relatively low heterogeneity between cohorts. Both fixed effects and
random effects models result in similar effect estimates (fixed effect model: OR, 0.782; CI, 0.614-0.995; random effects model: OR, 0.747;
CI, 0.559-1.000; P-values = .0458 and .05, respectively). B-D, Expression data of the SLC6A4 P2-driven isoform from tissue samples from
the jejunum: B, qPCR results showing jejunal mucosal expression of SLC6A4 P2 isoform and genotype correlation of the tag SNP rs2020938
representative for the polymorphic P2 region. C, Comparative expression analysis of IBS and healthy controls by qPCR. D, Correlation
analysis of nCounter expression data in TC carriers of rs2020938

gene expression, auditory disease and inflammatory disease. Nine

It remains unclear whether the deletion/insertion polymorphism

factors assembled in the overlay network have been implicated in

s/l in the P1 promoter region of the SLC6A4 gene plays a role in IBS

GI disorders (Figure 5A, highlighted in orange). Data reported in the

development.11 This prompted us to investigate the alternative pro-

GTEx portal (release v08, https://gtexportal.org/home/) confirmed

moter, P2. The s/l polymorphism has been associated with increased

that most of these genes are moderately to highly expressed in GI

susceptibility to stress-provoked psychopathologies20,30 that are

tissues (Figure 5B). Subsequent analysis of ChIP Atlas data (https://

comorbid with IBS. We wondered whether the gut-predominant iso-

chip-atlas.org/search) to collect further evidence and validate ePOS-

form might help to dissect the role of SERT in the GI tract.

SUM data revealed all predicted transcription factors but nine to be

A recent comprehensive meta-analysis based on more than 7000

included. Interestingly, eight of the predicted transcription factors

individuals, including more than 3400 IBS and 3600 control cases,

were found to indeed co-precipitate and thus interact with SLC6A4:

reported that the SLC6A4 s/l polymorphism correlated with the risk

Among those, ETS1, FOXP1, MITF, RAD21 and ZBTB7A are also in-

of IBS-C in Asians and Caucasians.31 Here, we show that the SLC6A4

cluded in the interaction network (Figure 5, Table S11).

P2 promoter drives expression in the gut mucosa and, predominantly, in the small intestine. Our finding that the P2-driven isoform

4 | D I S CU S S I O N

is predominantly expressed in the small intestine is supported by
data in the GTEx portal (https://gtexportal.org/home/). Of note, the
predominant expression of SERT within the small intestine is also

We have discovered a novel, functionally relevant cis-regulatory

in line with previous studies.32,33 The lack of robust expression of

promoter haplotype in the SLC6A4 gene that is associated with

the SLC6A4 P1-driven isoform in the small and large intestine chal-

IBS-C in females. This further supports the physiological relevance

lenges the role of the P1 s/l polymorphism in the gut. Furthermore,

of SERT in IBS pathogenesis and consolidates the importance of

how the P1 promoter-driven isoform could shape a GI phenotype is

the serotonergic pathway in regulating gut homeostasis and IBS

unknown. The reported association of the P1 promoter s/l polymor-

development.

phism with IBS-C may be attributed to comorbid conditions, such
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F I G U R E 4 Exon-exon junction expression data from different tissues modified from the GTEx portal (v8). The P1-driven isoforms are
represented by junction 15 and 16, whereas the P2-driven isoform is represented by junction 14 (marked in red), which shows a highly
prominent expression compared with 15 and 16 in the small intestine (terminal ileum, data from n = 187 donors included, median TPM
4.219). All other tissues, except the lung, show much lower expression levels (eg oesophagus n = 555 donors, median TPM 1.645, all others:
median TPM below 0.2). TPM, transcripts per million (adapted from Junction Expression of SLC6A4: ENSG00000108576.9 solute carrier
family 6 member 4 [Source: HGNC Symbol; Acc:HGNC:11050] GTEx portal: https://gtexportal.org/home/)

as behavioural phenotypes. This is supported by the fact that 80%

SLC6A4 variants and psychiatric comorbidity in IBS are very much in

of IBS patients present with some form of psychological comorbid-

line with the biopsychological model of IBS.36

ity. 2 However, the authors of the meta-analysis did not stratify for

Variants in the SLC6A4 promoter can affect the response to

comorbid phenotypes like anxiety and depression, so this remains

treatment. For example, IBS-D patients with the P1 l/l genotype

elusive at present.

respond better to the 5-HT3 receptor antagonist alosetron,37,37

How factors such as stress and trauma influence gene-

whereas IBS-C patients with the P1 polymorphism l/l respond

environment and gene-gene interactions has also not been addressed

poorly to the 5-HT4 receptor agonist tegaserod compared with s/l

Sex differences were recently described in the modulation

or s/s carriers.38 Therefore, our finding that the SNP rs2020938 is

of serotonin in the thalamus, and 5-HT-binding studies showed that

associated with IBS-C in females may be relevant to novel pharma-

5-HTTP may affect males and females differently. Furthermore, se-

cogenetic treatments.

to date.

31

rotonergic signalling is affected differently in males and females with

In vitro luciferase assays supported our initial hypothesis that

affective disorders, suggesting that sex-dependent availability of se-

the protective SNP rs2020938 in P2 reduces expression of the

rotonin transporters in the thalamus contributes to the risk of affec-

GI-predominant SERT isoform. Follow-up analysis of tissue sam-

tive disorders. 24,34,35 Recent reports of an association between rare

ples from IBS patients and controls showed that carriers of the
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F I G U R E 5 A, Network analysis B, GTEx expression data of the 52 transcription factors (highlighted in yellow) predicted to bind
differently within the polymorphic P2 promoter region. The factors coloured in orange have previously been implicated in GI disorders

rs2020938 minor allele seem to have higher SERT expression in

acts as a modifier. Moreover, single-tissue eQTLs analysis within the

the jejunum; this may confirm a functional impact of this SNP on

GTEx portal showed significant eQTL signatures for rs2020938 in

SERT expression. Further genotype-phenotype correlations in gut

brain regions such as the amygdala and the cerebellum for a tran-

tissue of IBS patients seem to corroborate our findings—carriers of

script termed AC006050.2 and for SUZ12P (SUZ12 polycomb re-

the protective C allele with lower expression of the serotonin trans-

pressive complex 2 subunit pseudogene) and SSH2 (slingshot protein

porter P2 promoter-driven isoform had softer stools. This is in line

phosphatase 2) in the tibial nerve, but in no other nerve or gut tissue.

with the trend for an association between TC/CC carrier status and

(Table S12). AC006050.2 and for SUZ12P have no annotated func-

softer stools observed within the German IBS-Net replication co-

tion. AC006050.2 seems to be a non-coding RNA, and SUZ12P is a

hort. Our genotype-phenotype correlations also agree with earlier

pseudogene. SSH2 belongs to the SSH phosphatase gene family com-

studies showing that 5-HT levels correlate negatively with SERT

posed of three members (SSH1, SSH2 and SSH3) known to control

expression15,22,23 in IBS-D, which is characterized by softer stools.

essential cellular functions, including invasion, migration and motil-

Decreased levels of 5-HT have also been reported in IBS-C22-24 and

ity. SSH2 was recently reported to drive proliferation in colon cancer

might be caused by increased SERT expression. This intriguing find-

stem cells.39 How these eQTL findings might relate to IBS remains

ing shows, for the first time, that bowel habits correlate with the car-

unclear.

rier status of polymorphisms within the SLC6A4 P2 promoter, which
drives expression in the GI tract.

The polymorphic P2 promoter region harbours more than 50
novel transcription factor binding sites. These transcription factors

The potential functional impact of rs2020938 is emphasized

have been annotated to three major networks, including gene ex-

by recent data in the OMNI database (https://omni.telentilab.com/

pression and cellular development, morphology and function, and

search=rs2020938/page=1) indicating that rs2020938 presumably

humoral immune response and inflammatory disease. Furthermore,
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the GTEx database shows that most of these transcription factors

GI phenotypes were not examined in control individuals, so

are robustly expressed in GI tissues, indicating a possible relevance

we cannot exclude that IBS patients were in the control sample.

to the pathogenesis of IBS. Interestingly, nine have been implicated

Moreover, because of symptom-based classifications and heteroge-

in GI disorders; for example, Nfil3 deficiency has been associated

neity, we cannot exclude that enrolled patients had the same diseases

with colitis, NFIL3 is a susceptibility gene for inflammatory bowel dis-

and aetiopathogenetic mechanisms. For genetic studies, a purely

ease,

40,41

and TCF7L2 has been implicated in colorectal cancer.

42,43

symptom-based IBS classification (based solely on bowel function) is

GO enrichment analysis recently revealed serotonin pathway

not specific enough to identify mechanistically diverse phenotypes

genes, particularly those involved in serotonin re-uptake, to be

of IBS or its subgroups.11 Therefore, additional parameters, as well

the most differentially expressed genes between IBS patients and

as intermediate phenotypes or quantitative traits, are mandatory

healthy controls.

44

Furthermore, interaction of eight of these pre-

to dissect genetic patterns underlying IBS and to correlate these to
symptoms/markers. As recently established by GENIEUR,46 deep

dicted transcription factors was proven based on ChIP Atlas data.
Regulation of expression by alternative promoters and various

phenotypic characterization of patients is mandatory and should

splicing isoforms leads to profound molecular heterogeneity. Within

be based on the following criteria: clinical examination and specific

GenBank, seven human SLC6A4 isoforms driven by the P1 and P2

questionnaires (assessing not only GI but also psychiatric comorbid-

promoters are currently annotated (AK313166 and AK308014 by P1

ity, personality traits and somatization), assessment of laboratory

and L05568, AK309538, AY902473, BC069484 and X70697 by P2)

parameters and tissue sampling to follow-up changes in expression

underlining the molecular heterogeneity of SLC6A4. Furthermore,

in certain candidates. Control individuals should be characterized in

11

gene expression is regulated by micro-RNAs (miRNAs) in IBS.

a similar way to avoid including IBS patients in the control sample.

Of note, the miR-16 family that we recently found to be down-

However, most of the samples analysed in this study were collected

regulated in IBS 45,46 was reported to modulate SERT expression

before the GENIEUR phenotyping tool was established, so do not

within the brain47 and presumably also regulates SERT expression

follow that standard.51 Some studies showed that the IBS subtype

in the GI tract. Furthermore, miR-24 was found to be upregulated,

may change over time, which is another limitation. For example, one

whereas SERT was downregulated in the intestinal mucosa of IBS-D

study found that IBS-C changed to IBS-D or vice versa in 14% of fe-

patients.48 In an animal model of IBS, miR-24 was found to trigger

male patients.52 In addition, many of our samples came from tertiary

symptoms including visceral pain.48 SLC6A4 regulation was recently

referral centres, so may not be generalizable to all IBS patients.

summarized in a comprehensive review.

49

Regulation of SLC6A4

Another limitation is the small number of samples in the differen-

expression is complex, and it is currently unknown how the differ-

tial expression analysis. However, a strength of our study is that we

ent isoforms are expressed and how miRNAs and/or polymorphic

analysed expression in the small and large intestine, unlike previous

sites modulate the various functions of the serotonergic system.

studies that focussed on only one or two gut regions.53

Bidirectional communication between the gut and the brain via the

In conclusion, we confirmed that the novel promoter P2 is the

brain-gut/gut-brain axis might be modified by cis-regulatory poly-

predominant driver of SERT expression in the gut and that a func-

morphisms that drive gene expression and control gene function in

tionally relevant SNP in SLC6A4 is associated with IBS-C in females.

specific subregions/organs differently.

This underlines the relevance of SERT in IBS pathogenesis. To what

Our study has some limitations. We combined data from 13 cen-

extent this SNP shapes the GI phenotype in IBS and how it interferes

tres from different countries, so methodological discrepancies exist.

with other brain-related genetic variants and impacts bidirectional

Only one SNP was genotyped, so we could not correct our results

communication between the gut and the brain remain unanswered.

for population stratification using genetic principal components. To

Our future studies within the international H2020 consortium

mitigate potential bias, we only included individuals of European an-

DISCOvERIE (Development, dIagnosis and prevention of gender-related

cestry. Since all participants were Caucasians, our association find-

Somatic and mental COmorbiditiEs in iRritable Bowel Syndrome In

ing may not equally apply to the other populations. Also, the SNP

Europe, www.DISCOvERIE.eu) that implemented GENIEUR guide-

genotype frequencies significantly deviated from the HWE expecta-

lines will allow us to investigate how these variants correlate with

tion in patients from the Greek cohort, which we cannot explain at

behaviour, pain perception and bowel habits and how far gene-gene

present. However, the estimated effect size and direction are in line

and gene-environment interactions affect individual susceptibility

with the overall results.

to chronic GI disorders. A better understanding of potential SERT

Another limitation is that we did not define the IBS phenotype
according to a uniform symptom classification—we used Rome II and/

regulators is of clinical importance and may provide insight into IBS
pathophysiology and SERT-directed therapeutic interventions.

or Rome III criteria. The Rome III criteria50 allow a wider variation in
diagnostic identification of IBS, particularly of the IBS subtypes. We
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